Perimenopause finally gets its own playbook

The American College of Obstetricians and Gynecologists (ACOG) has published a new clinical toolkit in Obstetrics & Gynecology to help clinicians better manage perimenopause — the hormonally turbulent transition that typically begins around age 47 and can precede menopause by years. Unlike menopause, which is marked by estrogen deficiency, perimenopause involves erratic hormonal fluctuations that can cause cycle irregularities, mood and cognitive changes, sleep disruption, abnormal bleeding, and sexual dysfunction.

The toolkit emphasizes that perimenopause is physiologically distinct and deserves its own clinical framework — not just a "wait and see" approach. Since no therapies are FDA-approved specifically for perimenopause, much of the care is off-label. Clinicians are encouraged to start with the clinical picture rather than routine hormone testing (which rarely correlates reliably with symptoms) and to tailor treatment using two main strategies: ovarian suppression via hormonal contraception, or systemic estrogen supplementation through menopausal hormone therapy — or a hybrid of both.

Key Takeaways

• Anticipatory guidance should begin before symptoms become severe, integrated into routine midlife care
• Routine hormone level testing is not recommended — levels fluctuate and don't reliably reflect symptoms
• A hybrid approach combining hormonal contraception with menopausal hormone therapy is a viable option
• Shared decision-making and individualized care are central to the framework

Why it matters: With millions of women navigating perimenopause and historically receiving little targeted guidance, this toolkit gives clinicians a practical, evidence-informed roadmap to address a stage of reproductive health that has long been under-managed.